Project Details
| Status | Active |
|---|---|
| Effective start/end date | 3/6/20 → 3/5/45 |
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and
- Sun, Kai (PI)
Project: Non Profit